Department of Rheumatology and Immunology

Peking University People's Hospital

The Department of Rheumatology and Immunology at Peking University People's Hospital and Center of Clinical Immunology at Peking University is one of the earliest and largest rheumatology centers in China. As a top National Key Center specializing in Rheumatology, the center has been titled as a National Center of Excellence in Rheumatology (certified in 2013), a National Key Laboratory in Clinical Immunology of the Ministry of Education of China (certified in 2005), an Innovation Team of the Ministry of Education of China (certified in 2011), a Beijing Key Laboratory (certified in 2012), the only International Cooperation Base in Rheumatic Diseases in Beijing (certified in 2015) and Asia Pacific League of Associations for Rheumatology (APLAR) Center of Excellence  (certified in 2016).

The center currently consists of 4 campuses in Beijing, Qingdao and Shijiazhuang respectively. The center comprises 110 hospital beds and 118 staff/researchers, including 19 Professors/Chief Physicians, 18 Associate Professors/Associate Chief Physicians, 11 Attending Physicians, 11 residents, 49 nurses and 9 technicians. There are 27 PIs, with around 50 SCI papers each year published in peer-reviewed journals including Lancet Rheumatology, JAMA Network Open, ARD and Nature Communications, etc.

The academic participation of the staff includes roles as past President of the International Leagues Associations of Rheumatology (ILAR), past President of the Asia Pacific League of Associations for Rheumatology (APLAR), past President of the Chinese Rheumatology Association, President of the Clinical Immunology Association of China, President of the Chinese Association of Women Physicians in Rheumatology and Immunology, member of WHO-ICC, member of the Chinese Rheumatology Association, etc. The staff also serve as associate editors of Clinical Rheumatology, International Journal of Rheumatic Diseases (IJRD), Seminars in Arthritis and Rheumatism and Journal of Gene Medicine and Immunology; chief editors of Chinese Journal of Rheumatology, Journal of Clinical Immunology and Rheumatology; editorial board members of Nature Reviews Rheumatology, Lancet Rheumatology, Rheumatology, Current Opinion in Rheumatology, Annals of the Rheumatic Diseases, Clinical and Experimental Rheumatology, Chinese Journal of Internal Medicine and National Medical Journal of China; reviewers of Lupus, Journal of  Rheumatology and over 10 other domestic and international journals.

A number of academic honors have been achieved, including "973" Chief Scientist, China Medical Board (CMB) Distinguished Professor, winners of the National Outstanding Youth Fund, winner of Wu Jieping - Paul Janssen Medical & Pharmaceutical Award, the Ministry of Education Cross-Century Talent, Medical Science and Technology Prize, winner of the Chinese Medical Science and Technology Award, University Scientific Research and Technological Progress Award, Beijing Nova, National Tech-Distinguished Talent, National Ten Thousand Talents Plan, Young Changjiang Scholar, etc.

The center has published over 850 papers with staff as first and corresponding authors in Nature Medicine, the Lancet Rheumatology, Immunity, JAMA Network Open, Cell Host & Microbe, Immunity, Annals of Internal Medicine, Annals of the Rheumatic Diseases, Arthritis & Rheumatology, Autoimmunity, etc, among which over 400 are SCI papers. The center edited, translated and participated in the editing of over 30 books in rheumatology including Rheumatology, Kelley's Textbook of Rheumatology, Sjögren’s Syndrome, etc.

The center focuses on rheumatic diseases such as rheumatoid arthritis, systemic lupus erythematosus and Sjögren’s syndrome. It has researched and developed more than 20 new specific markers and immune techniques in diagnosis, such as antibodies to the citrullinated HPVP, antibodies to citrullinated fibrinogen peptide, anti-mDNA, anti-nucleosome, anti- M3 receptor, anti-α-fodrin antibodies and SR-A. Meanwhile, over 10 novel immune-based therapies have been used, such as ld-IL-2 for SLE/RA/DM, T cell vaccination for SLE and RA.

Here are the publications of our department: https://english.pkuph.cn/expert_detail/594.html?_isa=1